Complement factor H antibody-associated atypical hemolytic uremic syndrome and eculizumab treatment

Atypical hemolytic uremic syndrome (aHUS) is a rare, chronic disease with frequent progression to end-stage renal disease. In the majority of these patients, there is a genetic or acquired disorder that causes the dysregulation of the alternative complement pathway. Factor H autobodies have been reported in 6-11% of the patients with aHUS. We aimed to present a case with anti-FH antibodyassociated aHUS with intractable relapses despite plasma exchange and immunosuppressive treatment, but remission was provided by the use of eculizumab.